IFLR1000
Nxera Pharma Co. Ltd, listed on the Tokio Stock Exchange, has entered into an exclusive licensing agreement with Santhera Pharmaceuticals under which Nxera will commercialize the drug AGAMREE® in Japan, South Korea, Australia and New Zealand. Concurrently, Nxera invests in SIX-listed Santhera Pharmaceuticals Holding AG.
Bär & Karrer - Switzerland,
January 13 2026